Drug Trial Radar · NCT05153226
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
640
Actual
Start
Mar 2, 2022
Primary completion
Mar 31, 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- DKMS gemeinnützige GmbHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Post-transplantation cyclophosphamide (PTCY) has become increasingly popular in the haploidentical HCT setting because it overcomes the HLA-mismatch barrier and levels GVHD risk. This advantage may also prove useful in the context of unrelated donor (UD) transplantation. GVHD prophylaxis for matched unrelated donor hematopoietic cell transplantation (alloHCT) in Europe is mainly conducted with ATG. Still, the burden of acute and chronic GVHD and especially of relapse remains high with both approaches for GVHD prevention. PTCY has not been tested against the current standard ATG for GvHD prophylaxis in large randomized trials. The goal of this trial is to compare the outcomes of PTCY and ATG for patients receiving unrelated donor PBSCT. PTCY-based prophylaxis promises to have beneficial net effects on immune reconstitution, GVHD and disease control, and thus might impact on patient survival.
Conditions
- Graft Vs Host Disease
- Peripheral Blood Stem Cell Transplantation
- AML
- MDS
- MDS/MPN
- CMML
Interventions
CyclophosphamideDrug
50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
ATGBiological
10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: from randomization
- GVHD- and relapse-free survival (GRFS)Time frame: from HCT
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Uniklinik RWTH Aachen
Aachen, Germany
Univeristätsklinikum Augsburg
Augsburg, Germany
Klinikum Chemnitz gGmbH
Chemnitz, Germany
Universitätsklinikum Köln
Cologne, Germany
St.-Johannes-Hospital Dortmund
Dortmund, Germany
Universitätsklinikum Dresden
Dresden, Germany
Uniklinikum Düsseldorf
Düsseldorf, Germany
Universitätsklinikum Essen (AöR)
Essen, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Germany
Universitätsklinikum Halle (Saale)
Halle, Germany
Universitätsklinikum des Saarlandes
Homburg, Germany
Universitätsklinikum Jena
Jena, Germany
Universitätsklinikum Schleswig-Holstein
Kiel, Germany
Universitätsklinikum Schleswig-Holstein
Lübeck, Germany
Universitätsmedizin Mainz
Mainz, Germany
Universitätsmedizin Mannheim
Mannheim, Germany
Philipps Universität Marburg
Marburg, Germany
Universitätsklinikum Münster
Münster, Germany
Klinikum Nürnberg Nord
Nuremberg, Germany
Universitätsmedizin Rostock
Rostock, Germany
Robert-Bosch-Krankenhaus
Stuttgart, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.